Bayer Loses First Phase of Roundup Trial, Now Will Face Liability
- Company faces more than 11,000 lawsuits over cancer in U.S.
- Analysts say decision may edge Bayer closer to a settlement
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
Bayer AG slumped after a second major defeat in U.S. litigation over claims that its Roundup weed killer causes cancer, shaving almost $8 billion from its market value and raising the likelihood of a costly settlement.